* European Commission approves extended indication for
Amgen’s Kyprolis (carfilzomib) for treatment of relapsed
multiple myeloma patients
Source text for Eikon:
Further company coverage:
…
The post BRIEF-Amgen says European Xommission approved extended indication for Kyprolis appeared first on NASDAQ.